What would be your approach to the consideration of the use of antiamyloid monoclonal antibodies for nonamnestic Alzheimer's disease with a positive biomarker for brain amyloid pathology?

Because treatment appropriateness is based on the stage of cognitive impairment, we base our evaluation on whether the patient meets criteria for mild cognitive impairment or early-stage dementia. We do not use cognitive testing cutoffs, even in amnestic Alzheimer's disease, as staging accounts for ...

I agree that appropriateness for Anti-Amyloid therapy is based on clinical stage and not presentation (amnestic vs non-amnestic). We have found, in our market at least, that the insurance companies want to see an MMSE or MOCA score that falls within the published appropriate use guidelines for these...